Literature DB >> 8141194

Prematurity prevention programs: an analysis of successes and failures.

J J Fangman1, P M Mark, L Pratt, K K Conway, M L Healey, J W Oswald, D L Uden.   

Abstract

OBJECTIVE: Our purpose was to assess the long-term results of established prematurity prevention programs. STUDY
DESIGN: A population cohort of pregnant women from two major urban health care organizations were examined. Rates and cost-benefit analysis of prematurity and patient, system, or physician failures were analyzed. During 1990 1143 pregnant women were prospectively reviewed.
RESULTS: A total of 11.8% of the mothers were high risk and responsible for 108 (50.2%) of the preterm deliveries. The preterm birth rate of all enrollees was 4.6%. One percent of the preterm neonates required level III care for complications. The average charge for a 35 week infant was 18 times, and a 36 week infant was five times more costly than a term infant. Patient, physician, and health care system failures occurred at different rates.
CONCLUSIONS: This preterm prevention program resulted in low preterm birth rates. Potentially preventable preterm births most often occurred as a result of patient and physician failures.

Entities:  

Mesh:

Year:  1994        PMID: 8141194     DOI: 10.1016/s0002-9378(94)70275-6

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

1.  A preterm birth prevention project in Nova Scotia, Canada.

Authors:  B A Armson; L Dodds; C Cervin; S Christie-Haliburton; K Rinaldo
Journal:  Matern Child Health J       Date:  2001-09

Review 2.  Community-based, population-focused preterm birth prevention programs - a review.

Authors:  Dana Vitner; Jon Barrett; Wendy Katherine; Scott W White; John P Newnham
Journal:  Arch Gynecol Obstet       Date:  2020-09-01       Impact factor: 2.344

3.  Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety.

Authors:  Helen Y How; Baha M Sibai
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.